獸用生物標記市場－全球產業規模、佔有率、趨勢、機會及預測：按動物類型、產品類型、應用、疾病類型、地區和競爭格局分類，2021-2031年

全球獸醫生物標記市場預計將從 2025 年的 11.1 億美元成長到 2031 年的 23.1 億美元，複合年成長率為 12.99%。

獸醫生物標記是指能夠指示動物正常生物過程、病理變化或藥物治療反應的生物分子、基因或特定特徵。市場成長的主要驅動力是動物慢性病發病率的上升，以及腫瘤學和心臟病學等領域對精準、非侵入性診斷日益成長的需求。伴侶動物數量的顯著成長進一步強化了這一上升趨勢，催生了對專業健康監測解決方案的需求。例如，歐洲寵物食品工業聯合會 (FEDIAF) 報告稱，到 2024 年，“將有 9,100 萬歐洲家庭至少擁有一隻寵物”，這凸顯了龐大的消費群對早期疾病檢測能力的需求。

儘管存在這些積極因素，但由於生物標記檢驗和商業化成本高昂，市場仍面臨許多障礙。這些高成本通常會導致診斷測試價格上漲，對發展中地區的寵物飼主和小規模獸醫診所帶來沉重的財務負擔。因此，這些經濟因素阻礙了診斷工具的廣泛應用，並限制了其進入整個市場。

市場促進因素

獸醫保健成本的顯著成長是加速採用先進生物標記解決方案的主要因素。隨著飼主越來越將寵物視為家庭成員，他們也越來越願意為高品質的醫療保健服務付費，包括心臟病和癌症等慢性疾病的複雜診斷檢測。這種經濟上的準備使得獸醫診所能夠將昂貴的生物標記檢測納入常規診療流程，使其從專業的科研工具轉變為關鍵的臨床資源。根據美國寵物用品協會於2025年6月發布的《2024年犬貓報告》，預計到2024年，美國寵物產業的總支出將達到1,520億美元，顯示該產業擁有龐大的資金基礎。這種購買力的提升直接支持了新型生物標記檢測組合的商業性永續性，並使飼主更容易獲得疾病的早期檢測。

此外，診斷生物標記分析技術的進步是推動這一趨勢的第二個主要因素，它使得在診療現場進行快速、精準的疾病分析成為可能。分子診斷技術和免疫檢測平台的發展簡化了特定生物標記的識別，使獸醫能夠即時實施循證治療策略，而無需完全依賴外部實驗室。這一轉變體現在將這些創新商業化的主要企業的財務成功上。例如，IDEXX Laboratories 於 2025 年 2 月公佈了其 2024 會計年度第四季和全年財務業績，總收入達到 38.98 億美元，這主要得益於對診斷工具的穩定需求。此外，市場機會不僅限於北美。正如英國寵物食品公司 (UK Pet Food) 在 2024 年指出的那樣，英國有 1,720 萬戶家庭飼養寵物，為這些先進的診斷技術創造了龐大的歐洲市場。

市場挑戰

生物標記檢驗和商業化所需的高昂資金負擔是全球獸醫生物標記市場發展的主要阻礙因素。生產商在研發和監管核可階段被迫承擔高額成本，迫使他們採取高價策略以確保投資回報。這種定價結構最終會轉嫁給終端消費者，導致診斷測試的價格往往過高，難以滿足標準的臨床應用需求。因此，獸醫往往不願意提案可能超出客戶經濟承受能力的診斷方法，阻礙了這些高精度工具的廣泛應用。

這些經濟壁壘限制了市場成長，因為先進的生物標記僅限於富裕的寵物飼主和專業轉診中心使用，無法成為普通獸醫護理的常規做法。如果目標消費族群無法承擔這些高昂的價格，市場規模將難以擴大。根據美國寵物用品協會的數據，到2024年，美國獸醫醫療總支出和產品銷售額將達到398億美元。目前的支出水準凸顯了寵物飼主已經承受的巨大經濟負擔，這使得將更昂貴的診斷方案推向市場變得更加困難。

市場趨勢

獸醫液態生物檢體解決方案的興起正在革新腫瘤學領域，它能夠非侵入性地識別循環腫瘤核小體和DNA。這項技術滿足了市場對簡單易用的篩檢設備的重要需求，這些設備能夠檢測血管肉瘤和淋巴瘤等常見癌症，從而避免進行複雜且有創的組織切片檢查。隨著獸醫將這些創新檢測方法納入早期疾病監測的常規流程，其商業性應用正在加速。例如，VolitionRx Limited在2025年3月發布的2024年全年財務報告中指出，該公司在2024年售出了約12萬份Nu.Q Vet癌症檢測產品，這表明基於血液的癌症篩檢方法在臨床應用方面取得了顯著成長。

同時，預防性健康管理和篩檢計畫的擴展正將市場重點從被動治療轉向主動健康維護。獸醫診所擴大將生物標記檢測納入無症狀動物的常規健康檢查中，力求在症狀出現之前識別潛在的心臟或腎臟問題。這種策略轉變推動了每次就診的診斷檢測頻率增加，而這些檢測並非僅限於疾病諮詢。近期的數據也證實了預防性檢測的增加。 IDEXX Laboratories 在 2024 年 8 月舉行的「2024 會計年度第二季財報電話會議」中報告稱，與上年同期相比，每次健康檢查的診斷頻率提高了 100 個基點，凸顯了預防性篩檢措施已有效融入日常獸醫實踐中。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球獸醫生物標記市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 動物類型（伴侶動物、繁殖動物）
  • 依產品類型（生物標記、試劑盒和試劑、生物標記讀取器）
  • 按應用領域（疾病診斷、臨床前研究等）
  • 依疾病類型（發炎/感染疾病、心血管疾病、骨骼肌疾病、腫瘤、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美獸醫生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲獸醫生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區獸醫生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲獸醫生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲獸醫生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球獸醫生物標記市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zoetis Inc.
• Virbac SA
• Life Diagnostics Inc
• INGENIUS BIOTECH SL
• Merck & Co., Inc.
• IDEXX Laboratories, Inc.
• Mercodia AB
• Antech Diagnostics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Veterinary Biomarkers Market is projected to expand from USD 1.11 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a compound annual growth rate of 12.99%. Veterinary biomarkers, defined as biological molecules, genes, or specific characteristics, function as indicators of normal biological processes, pathogenic changes, or responses to pharmacological treatments in animals. The market's growth is largely fueled by the increasing incidence of chronic diseases in animals and a growing need for precise, non-invasive diagnostics in fields such as oncology and cardiology. This upward trend is reinforced by the significant rise in the companion animal population, creating a demand for specialized health monitoring solutions. For example, 'FEDIAF' reported in '2024' that '91 million European households owned at least one pet', highlighting the extensive consumer base driving the need for early disease detection capabilities.

Despite these positive drivers, the market faces considerable obstacles due to the substantial costs involved in validating and commercializing biomarkers. These high expenses typically result in costly diagnostic tests, which can be financially burdensome for pet owners and smaller veterinary clinics in developing regions. Consequently, these economic factors limit the broad adoption of such diagnostic tools and restrict overall market accessibility.

Market Driver

The marked increase in veterinary healthcare spending serves as a key accelerator for the adoption of sophisticated biomarker solutions. As owners increasingly treat their pets as family members, there is a heightened willingness to pay for premium medical services, including intricate diagnostic tests for chronic ailments such as cardiac disease and cancer. This financial readiness enables veterinary clinics to incorporate expensive biomarker assays into standard practice, elevating them from specialized research instruments to vital clinical resources. Citing the American Pet Products Association's '2024 Dog and Cat Report' from June 2025, total U.S. pet industry spending hit $152 billion in 2024, demonstrating the immense financial backing of this sector. This enhanced purchasing power directly supports the commercial sustainability of new biomarker panels, facilitating broader access to early disease detection for animal owners.

Additionally, technological progress in diagnostic biomarker analysis acts as a secondary major driver, facilitating swift and precise disease profiling at the point of care. Developments in molecular diagnostics and immunoassay platforms have simplified the identification of specific biological markers, permitting veterinarians to implement real-time, evidence-based treatment strategies without total dependence on external labs. This transition is reflected in the financial success of leading companies commercializing these innovations. For example, Idexx Laboratories announced in February 2025, within their 'Fourth Quarter and Full Year 2024 Results', a total revenue of $3.898 billion, fueled by consistent demand for diagnostic tools. Moreover, the market opportunity reaches beyond North America; as noted by UK Pet Food in 2024, 17.2 million UK households owned a pet, establishing a significant European audience for these advanced diagnostic technologies.

Market Challenge

The heavy financial load required for biomarker validation and commercialization acts as a major constraint on the Global Veterinary Biomarkers Market. Producers face high costs during research and regulatory approval stages, forcing them to adopt premium pricing strategies to secure a return on investment. This pricing structure is passed on to the end-user, leading to diagnostic tests that are frequently too costly for standard clinical use. As a result, the uptake of these high-precision tools is hindered, as veterinarians often hesitate to suggest diagnostics that might surpass their clients' financial limits.

Such economic barriers restrict market growth by limiting the use of advanced biomarkers to wealthy pet owners or specialized referral hospitals, preventing them from becoming standard practice in general veterinary care. The market faces difficulty scaling when the intended consumer base is unable to afford these premium prices. Data from the 'American Pet Products Association' indicates that in '2024', 'spending on veterinary care and product sales in the U.S. totaled $39.8 billion'. This level of current spending highlights the substantial financial burden already placed on pet owners, making it difficult to introduce further expensive diagnostic options into the market.

Market Trends

The rise of Veterinary Liquid Biopsy Solutions is revolutionizing the oncology landscape by allowing for the non-invasive identification of circulating tumor nucleosomes and DNA. This development meets a vital market demand for straightforward, accessible screening instruments capable of detecting common cancers like hemangiosarcoma and lymphoma, bypassing the need for complex invasive tissue biopsies. The commercial uptake of these innovative assays is gaining speed as veterinarians incorporate them into standard routines for early disease surveillance. For example, VolitionRx Limited reported in March 2025, within their 'Full Fiscal Year 2024 Financial Results', sales of roughly 120,000 Nu.Q Vet Cancer Tests in 2024, indicating a marked rise in the clinical application of blood-based cancer screening methods.

Concurrently, the growth of Preventive Wellness and Screening Programs is moving the market focus from reactive treatment to proactive health maintenance. Veterinary clinics are increasingly including biomarker panels in standard wellness check-ups for asymptomatic animals, seeking to identify sub-clinical cardiac or renal issues before symptoms appear. This strategic shift is increasing diagnostic usage rates per visit, separate from appointments for illness. Evidence of this rise in proactive testing is seen in recent data; Idexx Laboratories noted in their 'Q2 Fiscal Year 2024 Earnings Call' in August 2024 that diagnostic frequency per wellness visit grew by 100 basis points year-over-year, highlighting the successful incorporation of preventive screening measures into routine veterinary practice.

Key Market Players

• Zoetis Inc.
• Virbac SA
• Life Diagnostics Inc
• INGENIUS BIOTECH SL
• Merck & Co., Inc.
• IDEXX Laboratories, Inc.
• Mercodia AB
• Antech Diagnostics Inc

Report Scope

In this report, the Global Veterinary Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Biomarkers Market, By Animal Type

• Companion Animals
• Production Animals

Veterinary Biomarkers Market, By Product Type

• Biomarkers
• Kits & Reagents
• Biomarker Readers

Veterinary Biomarkers Market, By Application

• Disease Diagnostics
• Preclinical Research
• Others

Veterinary Biomarkers Market, By Disease Type

• Inflammatory & Infectious Diseases
• Cardiovascular Diseases
• Skeletal Muscle Diseases
• Tumor
• Others

Veterinary Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Biomarkers Market.

Available Customizations:

Global Veterinary Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Companion Animals, Production Animals)
  • 5.2.2. By Product Type (Biomarkers, Kits & Reagents, Biomarker Readers)
  • 5.2.3. By Application (Disease Diagnostics, Preclinical Research, Others)
  • 5.2.4. By Disease Type (Inflammatory & Infectious Diseases, Cardiovascular Diseases, Skeletal Muscle Diseases, Tumor, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Product Type
  • 6.2.3. By Application
  • 6.2.4. By Disease Type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Disease Type
  • 6.3.2. Canada Veterinary Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Disease Type
  • 6.3.3. Mexico Veterinary Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Disease Type

7. Europe Veterinary Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Product Type
  • 7.2.3. By Application
  • 7.2.4. By Disease Type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Disease Type
  • 7.3.2. France Veterinary Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Disease Type
  • 7.3.3. United Kingdom Veterinary Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Disease Type
  • 7.3.4. Italy Veterinary Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Disease Type
  • 7.3.5. Spain Veterinary Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Disease Type

8. Asia Pacific Veterinary Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Product Type
  • 8.2.3. By Application
  • 8.2.4. By Disease Type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Disease Type
  • 8.3.2. India Veterinary Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Disease Type
  • 8.3.3. Japan Veterinary Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Disease Type
  • 8.3.4. South Korea Veterinary Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Disease Type
  • 8.3.5. Australia Veterinary Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Disease Type

9. Middle East & Africa Veterinary Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Product Type
  • 9.2.3. By Application
  • 9.2.4. By Disease Type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Disease Type
  • 9.3.2. UAE Veterinary Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Disease Type
  • 9.3.3. South Africa Veterinary Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Disease Type

10. South America Veterinary Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Product Type
  • 10.2.3. By Application
  • 10.2.4. By Disease Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Disease Type
  • 10.3.2. Colombia Veterinary Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Disease Type
  • 10.3.3. Argentina Veterinary Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Virbac SA
• 15.3. Life Diagnostics Inc
• 15.4. INGENIUS BIOTECH SL
• 15.5. Merck & Co., Inc.
• 15.6. IDEXX Laboratories, Inc.
• 15.7. Mercodia AB
• 15.8. Antech Diagnostics Inc

16. Strategic Recommendations

17. About Us & Disclaimer